IOVA — Iovance Biotherapeutics Cashflow Statement
0.000.00%
Last trade - 00:00
- $2.23bn
- $1.87bn
- $1.19m
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | -198 | -260 | -342 | -396 | -444 |
Depreciation | |||||
Amortisation | |||||
Non-Cash Items | 27.5 | 50.3 | 86.6 | 96.7 | 70.8 |
Unusual Items | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | 10 | 2.98 | 24.6 | -2.89 | -10 |
Change in Accounts Receivable | |||||
Change in Inventories | |||||
Change in Prepaid Expenses | |||||
Change in Accounts Payable | |||||
Change in Accrued Expenses | |||||
Other Operating Cash Flow | |||||
Cash from Operating Activities | -159 | -205 | -228 | -293 | -362 |
Capital Expenditures | -6.92 | -46.8 | -37.6 | -20.4 | -22.3 |
Purchase of Fixed Assets | |||||
Other Investing Cash Flow Items | 96.9 | -271 | 37.7 | 277 | -133 |
Acquisition of Business | |||||
Sale/Maturity of Investment | |||||
Purchase of Investments | |||||
Cash from Investing Activities | 90 | -318 | 0.132 | 256 | -155 |
Financing Cash Flow Items | -0.312 | -0.284 | — | -2.65 | -2.79 |
Other Financing Cash Flow | |||||
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | 6.13 | 576 | 239 | 190 | 463 |
Foreign Exchange Effects | |||||
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | -62.7 | 53.4 | 11.5 | 154 | -56.8 |